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Abstract Neuroenhancement involves the use of
neurotechnologies to improve cognitive, affective or
behavioural functioning, where these are not judged to
be clinically impaired. Questions about enhancement
have become one of the key topics of neuroethics over
the past decade. The current study draws on in-depth
public engagement activities in ten European countries
giving a bottom-up perspective on the ethics and desir-
ability of enhancement. This informed the design of an
online contrastive vignette experiment that was
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administered to representative samples of 1000 respon-
dents in the ten countries and the United States. The
experiment investigated how the gender of the protago-
nist, his or her level of performance, the efficacy of the
enhancer and the mode of enhancement affected support
for neuroenhancement in both educational and employ-
ment contexts. Of these, higher efficacy and lower per-
formance were found to increase willingness to support
enhancement. A series of commonly articulated claims
about the individual and societal dimensions of
neuroenhancement were derived from the public en-
gagement activities. Underlying these claims, multivariate
analysis identified two social values. The Societal/
Protective highlights counter normative consequences
and opposes the use enhancers. The Individual/
Proactionary highlights opportunities and supports use.
For most respondents these values are not mutually ex-
clusive. This suggests that for many neuroenhancement is
viewed simultaneously as a source of both promise and
concern.
Keywords Neuroenhancement . Social values .
Empirical ethics
Introduction
Neuroenhancement is a controversial area of science
and technology that has the potential to influence fun-
damental aspects of our mental and behavioural func-
tioning. It involves the use of neurotechnologies to
improve cognitive, affective or behavioural functioning,
where these are not judged to be clinically impaired [1].
There are a range of technologies that might result in
neuroenhancing effects, such as pharmaceuticals, brain-
computer interfaces, gene editing and brain stimulation.
To date, much of the neuroethics literature has focused
on the off-label use of pharmaceuticals intended for the
treatment of medical conditions, such as attention deficit
hyperactivity disorder (ADHD) or narcolepsy [2], and
more recently, on transcranial electrical brain stimula-
tion [3–5]. While surveys suggest that some students,
academics and medical professionals use prescription
substances to enhance their cognitive performance [2,
6–8, 9], the precise extent of this practice is difficult to
ascertain. For example, estimates of student use range
from 5%–35% depending on the definition of enhance-
ment and the method of assessment [10]. Questions
around enhancement have become one of the key chal-
lenges for neuroethics and over the past decade the topic
has received considerable attention in both academia and
in popular culture [11, 12]. A number of national and
international reports have addressed the social, legal and
ethical aspects of neuroenhancement. The reports call for
more research into the effects and side effects of available
methods and express varying degrees of scepticism about
the prospect of meaningfully improving upon normal
capacities ([13]; BMA [14, 15]; Comitato Nazionale per
le Bioetica [16]; NCOB [17]; PCOB [18]).
Several researchers have highlighted the importance
of unders tanding publ ic a t t i tudes towards
neuroenhancement and of involving a wide range of
stakeholders in deliberations about the governance of
the field [19, 20].
An influential report on human enhancement by the
European Parliament’s Science and Technology Options
Assessment agency was among the first to call for the
establishment of public fora, where citizens could en-
gage in dialogue about the opportunities and challenges
of enhancement, in order to work towards a normative
framework for the governance of enhancement technol-
ogies [15].
In recent years a body of empirical studies about
public views in relation to enhancement has
emerged. In 2004 the European Social Survey asked
respondents if they approved of ‘the use of medi-
cines to improve the memory of healthy people’. Of
the ten countries featured later in this paper, on
average 53% of the respondents in national samples
approved or strongly approved, while 23%
disapproved [49]. A Eurobarometer in 2010 found
that 58% thought that ‘brain and cognitive enhance-
ment’ would have a ‘positive effect’ on ‘our way of
life over the next 20 years’ with 12% saying that it
would have a ‘negative effect’ [21]. Overall, the
surveys show considerable interest in enhancement
and at most one in five respondents expressing
scepticism.
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Findings from smaller scale and in-depth studies
about the ethics of enhancement reveal greater scepti-
cism and show that the public’s views are broadly
similar to those discussed in the academic literature,
namely, concerns about the safety of enhancers and their
potential for coercion and inequity are paramount [22].
Drawing on experimental methods to study university
students’ willingness to use cognitive enhancing drugs,
Sattler and his team found evidence of a pragmatic
approach to decision-making [23], where perceptions
of acceptability were influenced by a variety of situa-
tional factors including peer pressure, the user’s perfor-
mance level in the relevant domain, the safety and
efficacy of the enhancer and the person’s characteristics,
such as their moral evaluation of enhancement, prior
use, and study habits and motivation [24, 25]. Sub-
stances with severe side effects elicited lower willing-
ness to use than those with moderate or slight side-
effects, and willingness was significantly higher when
the hypothetical student depicted in the experiment was
a low performer, compared to average or high per-
formers [24]. It is notable that two out of three respon-
dents in Sattler et al.’s sample said they would not use
cognition enhancing drugs under any circumstances.
While Sattler’s factorial surveys focused on the uni-
versity context to investigate the determinants of will-
ingness to use enhancers, a series of contrastive vignette
experiments by Fitz et al. [26] studied public attitudes to
the most commonly discussed ethical issues around
neuroenhancement; safety, pressure to use, fairness and
authenticity. They found that respondents were signifi-
cantly more likely to approve of neuroenhancement and
accept its risks if the aim was restorative rather than
enhancing, irrespective of whether the method was
pharmacological or neuro-stimulation. They found evi-
dence for the hypothesis that attitudes towards the risks
and benefits of enhancement differ according to the
perceived prosocial nature of the subject’s occupation
who engages in the enhancement practice. The study
also showed that an enhancer that supports greater effort
is preferred to an enhancer that replaces effort. Irrespec-
tive of the technology in question, respondents reported
a high likelihood of using enhancers in the workplace.
Furthermore, in terms of fairness the study showed that
the public embraces meritocratic views and cherishes
hard work [26]. A subsequent study investigated public
attitudes to restorative and enhancing uses of pharma-
ceuticals. Across twelve cognitive, affective and social
domains it found that respondents were significantly
more comfortable with interventions towards the norm
(restoration) than with interventions above the norm
(enhancement) [27]. At the same time, stakeholder stud-
ies reveal a great deal of ambivalence and the presence
of conflicting ethical principles when individuals con-
sider the acceptability of enhancement [28].
Situated within experimental neuroethics the present
study was designed to provide further empirical input
into discussions about the contours of a normative
framework for neuroenhancement. In line with the
Forlini and Hall [28] call that research should assess
the morally significant values that motivate public atti-
tudes, the study includes a focus on values and the ways
in which these influence the pragmatic approach to
decision-making identified in earlier studies. To our
knowledge, this is the largest investigation of public
attitudes to neuroenhancement to date.
Methods
The study reported here was part of a 39-month Euro-
pean project called Neuroenhancement – Responsible
Research and Innovation (NERRI), conducted in ten EU
Member States. The project was designed to facilitate
public dialogue about the ethics and desirability of
neuroenhancement (referred to hereafter as NE). The
project ran more than sixty public engagement events
in the form of focus groups, workshops, debates, exhi-
bitions, a hackathon and science cafes on the subject of
NE. The events involved scientists, ethicists, teachers,
students, military officers, medical professionals, entre-
preneurs and members of the public. The events ranged
from 8-person focus groups to 500 or more attending
exhibitions or other live events, and from hour-long
group discussions to workshops and activities spanning
several days. The outcome of these events was a qual-
itative appreciation of issues of interest and concern
about NE [29]. These insights served as the basis for
developing an online survey, in which the aim was to
gain a more robust understanding of the public’s views
about neuroenhancement in the participating EU coun-
tries. The United States of America was included in the
survey when a project participant moved there.
The survey comprised two main sections:
1) two experiments focused on the public’s views
about neuroenhancement in an educational and em-
ployment context;
Bottom Up Ethics - Neuroenhancement in Education and Employment 311
2) a series of broader attitude questions related to
neuroenhancement;
The experiments employed the contrastive vignette
technique [30], which is emerging as a powerful method
for experimental neuroethics research [26], combining the
causal analysis of experimentation with the large sample
sizes typical of survey research. Broadly speaking, a vi-
gnette is a short account of a situation in which a protag-
onist with certain characteristics faces a dilemma and
choses one of two available courses of action. In its sim-
plest form the contrastive techniques involve presenting
minimally different versions of a single vignette to respon-
dents and asking all participants the same set of questions.
The minimal contrasts allow experimenters to investigate
how a single factor influences people’s responses.
An advantage of using vignettes for our study is that
only a minority of people in our public consultation
events had heard about NE. As such, asking respondents
for a judgement on NE without providing them with
some information about the topic would not have yielded
meaningful results. With vignettes, it is possible to give
an accessible and non-technical account of NE, embed-
ding the technology in contexts familiar to respondents.
Experiment 1 & 2 – Education and Employment
It has been established in the literature that therapeutic
interventions on the brain are generally not seen as
problematic by the public. However, use by non-
clinical groups in certain life world situations, such as
education or work, appears more contested. Such use
has been among the foci of the neuroethics literature
[31, 32], and was often raised by members of the public
during our engagement activities, leading to lengthy
discussions of the possible personal and societal benefits
and risks of NE. Following Cohen’s [33] typology of
enhancement technologies, the situations depicted in the
education and employment experiments broadly fall
into the same category. They describe reversible, non-
genetic, biological enhancements that individuals
choose for themselves. The enhancement targets the
upper bounds of abilities that people already possess.
It is somewhat debatable whether the enhancements
described in the life world contexts of education and
employment should be considered positional (relative to
others) or absolute (of intrinsic value) goods [34].
Respondents were presented with two vignettes, one
featuring NE in education, the other NE in employment.
The order of presentation of the two contexts was
randomised. The experiments were designed to assess
whether the type of enhancing technology, its efficacy,
the gender of the user, and the user’s current level of
performance shape attitudes to NE.
Efficacy has been shown to be an important factor
modulating attitudes towards enhancement [24]. It was
also a key question in the qualitative consultation exer-
cises, where a recurrent issue raised by the participants
was how well NE actually works. This suggests that both
pragmatic and moral assessments may be predicated on
such basic facts about the interventions.We hypothesized
that a smaller (10%) improvement compared to a larger
(50%) improvement would elicit different responses,
with higher efficacy making NE more acceptable, be-
cause more significant benefits might outweigh per-
ceived risks and other considerations. In relation to the
performance of the protagonist earlier studies established
that lower performance correlates with higher levels of
support [24]. We hypothesise that, with the prospect of a
serious loss as a result of failing an examination or losing
one’s job, there would be greater propensity to accept the
possible risks of enhancement [35].
Furthermore, a scenario where a protagonist is acting
to avert such a loss might be perceived as a quasi-
therapeutic intervention [27], and thus seen as more
permissible. In our public consultations, discussions
often revolved around ‘pills’ and ‘electrical brain stim-
ulation’ as two of the currently available methods of NE.
The public can draw on a great degree of life-world
experience in relation to pills, and a significant propor-
tion of the neuroethics discussion has also focused on
this type of NE. Electrical brain stimulation devices are
more recent but their neuroenhancing effects [4], com-
mercial availability, and uptake in the DIY community
[36] have sparked debates and proposals about the reg-
ulation of such cognition enhancing devices [37]. We
sought to investigate whether contrasting these two
technologies, the more familiar, pharmacological inter-
vention with the less familiar, technological one, would
influence attitudes. We also investigate whether the
gender of the person engaging in NE would affect
responses. The analysis of experimental effects is sub-
sequently complemented by the inclusion of
sociodemographic characteristics to assess whether
these correlate with certain attitudes.
Each factor had two levels; gender (male/female);
type of enhancer (pill/device); enhancer efficacy (10%
or 50% improvement), and current performance
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(good/failing). The 16 vignettes each present a short
story in which the protagonist confronts a problem,
which leads to a decision to use NE. Having read the
vignette, respondents answer the same set of questions,
capturing the outcome variables of interest. Respon-
dents were not aware of the other conditions. The hy-
potheses relating to the four factors are tested with
different versions of the vignette. As respondents see
only one vignette this acts against the ‘good respondent’
effect, the desire to conform to mainstream expectations
on moral issues [38].
Communicating possible risks as well as benefits was
deemed important to make the scenarios more realistic
and life-like. For employment, the risk was described as
‘occasional insomnia’, similar to Fitz et al.’s (2013), and
Sattler’s studies [24]. For education, the risk was de-
scribed as ‘some people get a headache after the effect
wears off’. Box 1 shows the different versions of the
education and employment vignettes.
Box 1 Education and Employment Vignettes – En-
glish language versions; first names were adapted to
local equivalents
Employment:
(GENDER Paul/Jack/Emily/Sarah) is in his/her mid-30s and
works full-time at a big company. Recently, his boss told him
that last year his work successfully (PERFORMANCE met /
failed) to meet the company’s expectations. Paul is determined
to get a promotion. This raised Paul’s fears that he could lose his
job. He recently came across the idea of using (TYPE OF
ENHANCER a pill / device) that promises to somewhat /
substantially increase a healthy person’s concentration and
memory, by about (ENHANCER EFFICACY 10% / 50%). (for
device only: It delivers tiny electrical currents to stimulate
certain areas of the brain using small sticky pads attached to the
outside of the head for about 15 min.) In some people, the pill /
device can cause occasional insomnia, but there are no known
long-term side effects. He decides to give it a try.
Education:
(GENDER Emily/Jack/Sarah/Paul) is in his/her early twenties and
studying full-time at university. His/Her results so far have been
(PERFORMANCE good / below average). S/he is currently
preparing for his/her examinations. While s/he feels
overwhelmedwith howmuchwork s/he has to do, she is aiming
for the top grade. / She feels overwhelmedwith howmuchwork
she has to do and fears that she may fail the exam. Recently s/he
heard about a (TYPE OF ENHANCER pill / device), which
promises a (ENHANCER EFFICACY small / significant im-
provement in the speed of learning in healthy people, but still
about 10% / by about 50%). (for device only: It delivers tiny
electrical currents to stimulate certain areas of the brain using
small sticky pads attached to the outside of the head for about
15 min.) Some people get a headache after the effect wears off,
but there are no known long-term side effects. She decides to
give it a try.
Respondents were randomly allocated a vignette
from both contexts and were asked a number of ques-
tions after each presentation. Here we report on one key
outcome measure:
& In (name of protagonist)‘s shoes, would you make
the same choice?
We will refer to the outcome of this question as the
respondent’s ‘willingness to use NE’. The full set of
questions and results are available upon request. Re-
sponses were recorded on an 11-point scale, ranging from
−5 to +5. We assumed that respondents could imagine
themselves in the same predicament and to be able to
decide whether they would support the protagonist’s
choice or not. We also assumed that this question, inviting
a participant script [39], would induce a more active
involvement in the situation than a question asking about
the extent to which they approve or support the choice or
approve/disapprove of NE in general – a non-participant
script.
Claims about Neuroenhancement
After experiments 1 & 2 respondents were asked to read
the following definition of neuroenhancement, which
was intended to provide a neutral account of NE intro-
ducing some key ideas without influencing respondents
to lean either way in their assessment.
Scientists are learning more about how our brains
work – how we remember, how we think, how we
feel and how we perceive the world. This research
is driven by the desire to understand the brain and
to find treatments for conditions like Alzheimer's,
Parkinson's, stroke, and depression. It is hoped
that this work will result in new ways of interven-
ing in brain functions to improve the mental abil-
ities and sensory capacities of patients. At the
same time, such research might also bring about
ways of enhancing the capacities of Bhealthy^
people as well (for example: improve concentra-
tion or increase memory). This is called neuro-
enhancement. The stories you read on the previ-
ous pages are just two examples of many possible
situations. Some are optimistic about neuro-
enhancement and think that we will be able to
improve our abilities. Others are doubtful because
Bottom Up Ethics - Neuroenhancement in Education and Employment 313
the brain is very complex and so little is known
about how it functions.
In the course of the public engagement activities
conducted throughout Europe (the United States was
not involved in this part of the project), researchers
met regularly to discuss their experiences, insights and
the issues raised by the participants. A number of recur-
ring themes included the personal and social conse-
quences of NE, therapy and the duty of care, the use of
technology to aid human achievement, the future of
humanity, potential misuse and regulation. From these
themes, the research group identified fourteen common-
ly mentioned claims about neuroenhancement and the
use of technological interventions in human achieve-
ment. These claims may be seen as the results of a
bottom-up approach to identifying moral and other con-
siderations thought to be of relevance by the public.
Box 2 Claims about neuroenhancement
In the survey, the following instructions were presented. BHere are
some views that people have expressed about
neuroenhancement of healthy individuals, and its wider
implications for society. Please read the statements below and
show how much you agree or disagree with them, using the
scale provided (−5 to +5).
1. People should be content with their talents and abilities and not
use artificial means to improve their performance
2. It is an expression of human nature to try to overcome the
limitations of our body and mind
3. People’s achievements should come from their own effort and
not from pills and devices
4. I can imagine neuro-enhancement opening up fascinating new
opportunities
5. Some people will use neuro-enhancers to cope with increasing
demands in life
6. As life gets more pressured, neuro-enhancement may be the
only way out
7. It is essential that public authorities oversee and control
neuro-enhancement
8. Only people with a medical problem should have access to
neuro-enhancement
9. People need to be protected from pressures to use
neuro-enhancers
10. If a neuro-enhancer is safe, it should be available as a consumer
product
11. Neuro-enhancement should never be used on children
12. Neuro-enhancement should be available to all those whomight
want it
13. Neuro-enhancement will increase competition between people
14. Neuro-enhancement will threaten social cohesion
Responses were recorded on an 11-point scale, from
Strongly disagree (−5) to Strongly agree (+5).
Design and Respondents
The survey was developed using the Qualtrics web
platform. The vignettes and the accompanying ques-
tionnaire were designed by the NERRI research
group. Translation from English into the national
languages was undertaken by members of the re-
search group. Assiduous attention was paid to ensur-
ing comparability of meaning of words and phrases.
The vignettes underwent qualitative piloting in focus
groups conducted by the Austrian team. Subsequent-
ly, the draft survey was piloted on 200 respondents
in the UK. Field work was conducted between Jan-
uary and February 2016 in Austria, Denmark, Ger-
many, Hungary, Italy, the Netherlands, Portugal,
Spain, UK and the USA by the commercial compa-
ny Respondi, which coordinates double opt-in access
panels of respondents for online surveys. In Iceland,
the fieldwork was carried out by Gallup, using the
same quotas. In each country quota samples of per-
sons 18 years and above, approximating the national
profile of age groups, gender and level of education
(tertiary or not) were selected, N = 11,716. The ques-
tionnaire included two trap questions to automatically
disqualify respondents speeding through the survey;
some 400 per country on average. Demographic
information was collected at the beginning.
In the survey, the experimental vignettes were the
first block of questions, followed by respondents’
level of agreement with claims about NE. The ratio-
nale for this ordering was to ensure that the effects
of the experimental treatments (gender, technology,
efficacy and performance) would not be influenced
by the substantive content of the claims about NE.
In other words, the claims might introduce respon-
dents to arguments about NE that they had not
previously encountered and these arguments might
set the context for responding to the vignettes. Were
this to have occurred it would not be possible to
claim that changes in responses to the vignettes
could be confidently attributed solely to the experi-
mental treatments. However, with this ordering of
the questions, it is possible that the experimental
treatments created a context effect for responses to
the claims, a possibility that we investigate.
In reporting the results of the survey, we reverse the
order as the claims about NE provide informative de-
scriptive information on respondents’ assessment of
arguments for and against NE.
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Results and Discussion
Claims about Neuroenhancement
As described above, this section of the survey included
14 claims derived from a series of public engagement
activities. We report descriptive analyses of the level of
agreement to these claims and then turn to multivariate
methods to explore, whether there are any latent vari-
ables underlying the responses.
Table 1 shows that there is strong agreement among
respondents that neuroenhancement should not be used
on children. There is also strong agreement that NE
should be controlled by public authorities, that people’s
achievement should come from their own efforts instead
of technological aids, and that people need to be
protected from pressures to use enhancers. This suggests
that NE is viewed as a technology with significant
potential for causing harm and leading to undesirable
outcomes, so strong red lines need to be drawn and
mechanisms of control put in place. However, there
are also indications that the desire to overcome our
limitations is an integral part of being human, hinting
at a view of human nature as malleable and open to
improvement. While this position is strongly held by
around 50% of respondents, the same proportion indi-
cated that people should be content with their talents and
abilities and not use artificial means to improve perfor-
mance. Together with the statement about the
importance of people’s achievement coming from effort,
this may be interpreted in multiple ways. Perhaps the
public is sensitive to distinctions between different ways
of pushing the boundaries of what humans can accom-
plish. While overall it may appear desirable to surpass
our mental and physical limitations, certain means of
doing so, such as pills and devices, are still unaccept-
able. It seems that the value of effort is paramount, and a
large proportion of respondents hold the view that the
‘natural’ distribution and level of talents and abilities
should not be tampered with technologically. The
boundaries of where and how the human pursuit of
improvement becomes undesirable warrants further in-
vestigation. Recent evidence suggests that interventions
requiring the activity and agency of the subject are seen
more favourably than those that involve a pharmaceuti-
cal quick fix [40]. Half of the respondents strongly agree
that some people will use enhancers to cope with in-
creasing demands and that NE is likely to increase
competition among people. On average, responses are
slightly above the mid-point of the scale on whether NE
will threaten social cohesion, whether NE will open
fascinating new opportunities and on questions
concerning the group of people who should have access
to NE. The average response to whether NE should be
available to all is just below the mid-point. Finally,
average responses are just below the mid-point, with
only 20.5% of respondents agreeing that NE might be
the only solution to increasing pressures in life.
Table 1 Mean, standard deviation and percentage in agreement with claims
Claim Mean (SD) % Agree*
Neuro-enhancement should never be used on children 8.0 (2.81) 76
It is essential that public authorities oversee and control neuro-enhancement 7.7 (2.52) 74
People’s achievements should come from their own effort and not from pills and devices 7.5 (2.57) 69
People need to be protected from pressures to use neuro-enhancers 7.3 (2.51) 66
It is an expression of human nature to try to overcome the limitations of our body and mind 7.2 (2.18) 68
Some people will use neuro-enhancers to cope with increasing demands in life 7.2 (2.11) 71
People should be content with their talents and abilities and not use artificial means to improve their performance 6.7 (2.85) 57
Neuro-enhancement will increase competition between people 6.6 (2.64) 58
Neuro-enhancement will threaten social cohesion 6.0 (2.76) 45
I can imagine neuro-enhancement opening up fascinating new opportunities 5.9 (2.64) 46
Only people with a medical problem should have access to neuro-enhancement 5.7 (2.97) 45
If a neuro-enhancer is safe, it should be available as a consumer product 5.6 (3.00) 43
Neuro-enhancement should be available to all those who might want it 4.8 (3.22) 34
As life gets more pressured, neuro-enhancement may be the only way out 3.8 (2.83) 21
*0, 1, 2, 3: disagree; 4, 5, 6: neutral; 7, 8, 9, 10: agree
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Next, the claims are investigated with multivariate
methods. Using principal components analysis, two
components with eigenvalues larger than 1 were extract-
ed, which accounted for 43.5% of the variance in the
data. The components were found to be uncorrelated
(component correlation −0.077) hence it was appropri-
ate to use a Varimax rotation, treating the components as
orthogonal. The rotated component loadings are shown
in Table 2. A reliability analysis on the items belonging
to the two components indicated that the 14 questions
may be seen as 2 separate scales measuring distinct
concepts, with 7 questions in each scale. Given that
the 14 claims about NE were not designed to measure
specific latent constructs the interpretation of the two
scales is not entirely straightforward. However, it seems
justifiable to observe that scale 1 contains items that are
prescriptive and formulate views on how NE should be
dealt with. These items pertain more to the potential
harmful societal consequences of NE and involve pro-
tective measures. On the other hand, scale 2 contains
items that are more proactionary and individualistic in
nature. Hence, we label them ‘Societal/Protective (SP
for short) and ‘Individual/Proactionary’ (IP for short)
respectively. For the ‘Societal/Protective’ scale
Cronbach’s alpha = 0.74; while for the ‘Individual/
Proactionary’ scale Cronbach’s alpha = 0.73. Here, the
term proactionary is appropriated from Fuller’s work
[41] and is understood as an approach that is open to
taking individual and societal risks in order to achieve a
positive transformation of the human condition.
As described in the methods section, these 14 claims
were presented to respondents in a randomised order
following the two contrastive vignette experiments. Did
the vignettes create a context effect in the responses to
the 14 claims? To investigate this possibility regression
models were fitted using the experimental manipula-
tions as explanatory variables to predict scores on the
two scales separately. We found that a few of the sixteen
experimental conditions influenced the SP and IP scales.
Controlling for other variables, respondents who were
randomly allocated to an employment vignette with a
high performing protagonist scored on average 0.082
points higher on SP than respondents who were allocat-
ed to a low-performing protagonist (p < 0.01). For the
education context two experimental factors impacted
significantly on the responses to the claims. Respon-
dents allocated to a vignette with a male protagonist
instead of a female one scored on average 0.074 points
Table 2 Claims loading on societal protective and individual proactionary components
Rotated Component Matrixa
Claim Component
Societal / Pro-
tective
Individual /
Proactionary
People should be content with their talents and abilities and not use artificial means to improve
their performance
.708
People’s achievements should come from their own effort and not from pills and devices .722
It is essential that public authorities oversee and control neuro-enhancement .486
Only people with a medical problem should have access to neuro-enhancement .591
People need to be protected from pressures to use neuro-enhancers .571
Neuro-enhancement should never be used on children .449
Neuro-enhancement will threaten social cohesion .673
If a neuro-enhancer is safe, it should be available as a consumer product −.469 .567
Neuro-enhancement should be available to all those who might want it −.553 .509
It is an expression of human nature to try to overcome the limitations of our body and mind .578
I can imagine neuro-enhancement opening up fascinating new opportunities .678
Some people will use neuro-enhancers to cope with increasing demands in life .653
As life gets more pressured, neuro-enhancement may be the only way out .501
Neuro-enhancement will increase competition between people .564
aVarimax with Kaiser normalization, Coefficients below 0.4 suppressed
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higher on SP (p < 0.05) and those assigned to a vignette
describing a high performing protagonist vs those with a
low performing one scored on average 0.112 points
higher (p < 0.001).
For IP, a somewhat different pattern emerged. In the
employment experiments, a high efficacy enhancer was
associated with 0.097 points higher scores on IP com-
pared to a low efficacy intervention (p < 0.01). The same
was true for the education context, where a high efficacy
NE increased average responses by 0.060 points com-
pared to a low efficacy NE (p < 0.05). While the effects
are statistically significant, the regression coefficients
are marginal from a substantive point of view and the
explained variation is equally small (maximum R2 =
0.002, that is 0.2%).
There is a moderate negative correlation between the
two scales (Pearson’s r = −0.351, p < 0.001), showing, it
might be thought, that the two scales capture opposing
values. The idea of pairs of values in opposition is a basic
feature of a contemporary theory of values, Schwartz
places ten universal and core values in a circular structure
depending on whether they are in opposition or compli-
mentary. BOne oppositional pair is openness to change
versus conservatism. On this dimension, self-direction
and stimulation values oppose security, conformity and
tradition values^ ([42]: 269). Hence we would expect
those subscribing to individual proaction to be opposed
to societal protection. To test this idea we recoded the
original continuous variables into 3-point categorical var-
iables using a tertile split. Table 3 shows that some people
express agreement with both values simultaneously. It is
notable that the proportion of those scoring low on SP or
IP is very low, suggesting that themajority of respondents
can identify, to some extent, with the two value orienta-
tions. 40.7% of respondents scored high on SP while
having moderate scores on IP. 15% have high scores on
both scales. In total, 60.8% of respondents have high SP
scores, while 33.9% have high IP scores. This could be a
sign of genuine ambivalence expressed as the parallel
desire to protect societal values, while also pursuing
individual enhancement.
Now we turn to the discussion of the contrastive
vignette experiments. In a subsequent section, we will
analyse how the different value orientations captured by
the two scales are related to opinions expressed in the
experiment.
Contrastive Vignette Experiments - Neuroenhancement
in Education and Employment
We used ordinary least squares regression with the four
experimental manipulations (gender of protagonist; pill or
device; high or low performance and high or low efficacy)
included in the models as dichotomous - dummy -
variables.
We first consider the employment context and the
effects of the experimental manipulations, looking at
the entire dataset of 11 countries (N = 11,716). Table 4,
model 1 shows the regression coefficients of the experi-
mental manipulations. The protagonist’s gender and the
method of NE intervention were not significant predic-
tors of respondents’ judgments on whether they would
use an enhancer. However, respondents were more likely
to believe they would make the same decision to use the
enhancer if the protagonist’s performance was low (β =
−0.355; p < 0.001), and if the enhancer’s efficacy was
high (β = 0.307, p < 0.001). In substantive terms, the
effect of the experimental manipulations was low, yield-
ing a change of around 0.3 units on the 11-point scale.
The amount of variation explained by the model is 0.5%.
In model 2, sociodemographic indicators are added.
The effect of the experimental manipulations is only mar-
ginally affected, with the pattern of significant vs. non-
significant predictors remaining unchanged. On average,
female respondents gave lower scores than males on the
response variable, by close to half a unit on the 11-point
scale. Compared to the 18–24-year-old age group, those
aged 45–54 and 55 or above gave increasingly lower
scores on the response variable, while possession of a
university degree had no effect on the dependent variable.
Finally, model 3 includes the scales, SP and IP,
derived from the 14 claims about neuroenhancement
described in the previous section. The most striking
difference between models 2 and 3 is in the amount of
variation explained by the regressions. Including the
two scales increases the explanatory power of the model
Table 3 Cross tabulation of support for societal protective and
individual proactionary values
Individual/Proactionary value scale
Societal/Protective Value
Scale
0–3.33 3.34–6.66 6.67–10 Total
0–3.33 0.2% 0.3% 1.8% 2.3%
3.34–6.66 0.8% 19% 17% 36.8%
6.67–10 5.1% 40.7% 15% 60.8%
Total 6.1% 60% 33.9% 100%
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17-fold, with the pattern of significant and non-
significant variables staying the same. Controlling for
the other variables in the model, each unit increase on
the SP scale is associated with a 0.4-unit drop on the
response variable, while each 1-unit increase on the IP
scale corresponds to a 0.76-point increase on the depen-
dent variable. This suggests that respondents who
expressed concerns about the societal impacts of
neuroenhancement and favoured a cautious, protective
approach were less likely to endorse neuroenhancement
in an employment context. On the other hand, respon-
dents who showed agreement with the IP scale were
more likely to be in favour of enhancement.
Turning to the education context, Table 5, model 1
shows the regression coefficients of the experimental
manipulations on the key response variable. The varia-
tion explained by the models is similarly small - 0.6% -
but as in the case of the employment context, some
experimental manipulations exerted a significant effect
on responses. The protagonist’s gender was insignifi-
cant. A pill versus a brain stimulation device led to
lower average scores of around 0.3 units (p < 0.001).
The protagonist’s high performance compared to low
performance created lower willingness to use an en-
hancer (β = −0.274, p < 0.001), while higher efficacy
NE interventions led to higher willingness to use (β =
0.336, p < 0.001) NE. Model 2 shows that female re-
spondents expressed lower willingness to use a
neuroenhancer than males (p < 0.001). With reference
to the 18–24-year-old age group, those aged 35 or above
gave lower scores on the response variable, with the 55+
age group being most different to the youngest (β =
−0.803, p < 0.001). Having completed tertiary education
made no difference to the responses.
As in the employment context, the amount of variation
explained bymodel 3 is 15 times higher than that ofmodel
2 (R2 = 0.27). Controlling for the other variables, each unit
increase on the SP scale is associatedwith a 0.45-unit drop
on the response variable, while each 1-unit increase on the
IP scale corresponds to a 0.76-point increase.
It is important to note that the two contexts, education
and employment are not directly comparable, because the
depicted side effects (headache vs occasional insomnia),
benefits (speed of learning vs memory and concentration)
and the stakes involved in the two scenarios (exam per-
formance vs job performance) were very different. Not-
withstanding these crucial differences, we find that the
protagonist’s level of performance and the enhancer’s
efficacy were significant considerations in both contexts,
which is in line with the pragmatic approach to NE
Table 4 Employment context regression coefficients
Employment Context Model 1 Model 2 Model 3
R-squared 0.005 0.016 0.278
Constant term 3.191 (0.067) 3.705 (0.113) 2.193 (0.198)
Protagonist’s gender (Reference category Female) 0.044 (0.060) 0.052 (0.060) 0.017 (0.051)
Protagonist’s performance Good (reference category Failing) −0.355*** (0.060) −0.347*** (0.060) −0.284*** (0.051)
NE-technology Pill (reference category: Device) 0.070 (0.060) 0.068 (0.060) 0.024 (0.051)
NE-efficacy High (reference category: Low) 0.307*** (0.060) 0.317*** (0.060) 0.233*** (0.051)
Respondent is female (reference category: Male) −0.491*** (0.060) −0.306*** (0.052)
Respondent age 25–34 (reference category 18–24) 0.041 (0.116) 0.016 (0.100)
Respondent age 35–44 (reference category 18–24) −0.202 (0.113) −0.172 (0.097)
Respondent age 45–54 (reference category 18–24) −0.275* (0.113) −0.204* (0.097)
Respondent age 55+ (reference category 18–24) −0.552*** (0.104) −0.283*** (0.089)
Respondent has a university degree (reference category: no degree) −0.004 (0.068) −0.101 (0.058)
Societal/Protective scale (11-point scale) −0.444*** (0.016)
Individual/Proactionary scale (11-point scale) 0.759*** (0.017)
Standard errors in parentheses
* p < 0.05; ** p < 0.01; *** p < 0.001
Model 1 includes the 4 experimental manipulations represented as dummy variables
Model 2 includes Model 1 plus sociodemographic indicators
Model 3 includes Model 2 and SP and IP scales
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identified by previous studies. Furthermore, in the educa-
tion context pills were associated with lower willingness
to use than brain stimulation. This finding is somewhat
surprising, given that pharmaceuticals are much more
familiar and we may reasonably assume that most respon-
dents have had experiences with them, while electrical
brain stimulation is a new and unfamiliar intervention.
However, the negative effect of pills in the education
context may be – at least partially – explained by long
standing concerns and discussions about the use
psychostimulant medications to address conditions such
as attention deficit hyperactivity disorder [43]. A break-
down by country of Table 5 showing the regression
coefficients (see Supplementary Material) shows that,
with the exception of the two value scales, there are no
consistent effects or remarkable differences between
countries. We doubt whether the interpretation of the
significant effects would justified.
Conclusion
Large scale survey research assessing the public’s sup-
port for neuroenhancement in general showed that many
people are in favour of the technology to improve the
abilities of healthy people. By contrast, the experimental
neuroethics literature indicates that people are sceptical
about non-medical applications of neurotechnologies,
identifying concerns about the safety of non-medical
interventions, risks associated with coercion, inequity
and authenticity. While therapeutic applications are gen-
erally acceptable, the enhancement of healthy people is
not [22, 26, 27].
The current study draws on extensive public engage-
ment activities to provide a bottom-up perspective on
the ethics of enhancement and to combine this with the
experimental and survey methodologies to investigate
the public’s views about NE.
In contrastive vignette experiments we assessed how
the gender of the protagonist, his or her level of perfor-
mance, the efficacy of the enhancer and the mode of
enhancement affects support for the use of NE in educa-
tional and employment contexts. Respondents were also
asked the extent to which they agreed or disagreed with
claims about NE that were frequently voiced in a series of
public engagement exercises. The results of the experi-
ments show that, as Sattler [24] had found, a pragmatic
approach to decision taking is in evidence. We find that
Table 5 Education context regression coefficients
Education Model 1 Model 2 Model 3
R-squared 0.006 0.018 0.270
Constant term 3.580 (0.069) 4.301 (0.117) 2.668 (0.205)
Protagonist’s gender (Reference category Female) −0.039 (0.062) −0.039 (0.062) 0.038 (0.053)
Protagonist’s performance Good (reference category Failing) −0.274*** (0.053) −0.286*** (0.062) −0.206*** (0.053)
NE-technology Pill (reference category: Device) −0.293*** (0.053) −0.286*** (0.062) −0.246*** (0.053)
NE-efficacy High (reference category: Low) 0.336*** (0.053) 0.341*** (0.062) 0.298*** (0.053)
Respondent is female (reference category: Male) −0.489*** (0.062) −0.301*** (0.053)
Respondent age 25–34 (reference category 18–24) −0.199 (0.119) −0.226* (0.103)
Respondent age 35–44 (reference category 18–24) −0.478*** (0.117) −0.446*** (0.100)
Respondent age 45–54 (reference category 18–24) −0.433*** (0.116) −0.363*** (0.100)
Respondent age 55+ (reference category 18–24) −0.802*** (0.107) −0.531*** (0.092)
Respondent has a university degree (reference category: no degree) 0.042
(0.070)
−0.054 (0.060)
Societal/Protective scale (11-point scale) −0.450*** (0.017)
Individual/Proactionary scale (11-point scale) 0.764*** (0.017)
Standard errors in parentheses
* p < 0.05; ** p < 0.01; *** p < 0.001
Model 1 includes the 4 experimental manipulations represented as dummy variables
Model 2 includes Model 1 plus sociodemographic indicators
Model 3 includes Model 2 and SP and IP scales
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caution prevails when it comes to applications beyond
medical use and the extent to which agreement to use
NEs can be modified by such factors is small.
Looking at the aggregate data across eleven countries
we find that there is no evidence that the use of NE by
men and women is viewed differently. In the education
context, there is more support for neuroenhancing elec-
trical brain stimulation rather than pills. This finding
may be related to a number of factors, including
unfavourable representations of drug taking and illegal
substances, or to widespread concerns and the high
media visibility of debates about psychostimulant
ADHD medications, as well as to the low levels of
public trust in the pharmaceutical industry [44].
In both the education and employment contexts, when
performance is already good respondents see little need
for further enhancement. By contrast, NE is more accept-
able when performance is low and an extra boost is
needed to avoid failure. In both contexts, higher efficacy
of NE is associated with greater willingness to use. There
is a clear generational divide in willingness to support;
the 18–24-year-old respondents show consistently higher
agreement to use and as age increases so does agreement
to use decline. When deciding whether to support NE or
not respondents focus more on the anticipated benefits
(efficacy) rather than the technology (pills or device).
The claims about NE show that over 70% agree that
NE should never be used on children and that it needs
oversight from public authorities. Yet, almost 70% agree
that overcoming the limitations of mind and body is in
human nature and more than 40% say that, if shown to
be safe, NEs should be available as consumer products.
Looking at the responses to these claims with multivar-
iate methods we find two distinct value orientations - the
societal protective and the individual proactionary stances.
These are strongly correlated with people’s views about
the use of enhancement in employment and education.
The pursuit of the good life is an inextricable part of
human nature, which is essentially underpinned by
values. In social psychology, the concept of social values
not only captures preferences and desires, but also ex-
presses what should, and what should not, be deemed
desirable. People feel committed to values, not because
they have to, but because theywant to [45].We have seen
the role of values very clearly in previous debates about
science and technology, such as the public controversy
over research on human embryonic stem cells. That
debate was characterised by the competing demands of
the values of ‘duty of care’ and the ‘sanctity of life’ [46].
In passing, with respect to enhancement it seems likely
that the value of the ‘duty of care’ lies behind the almost
universal support for therapeutic interventions. Tradition-
ally, social values have been seen as stable, enduring and
applying across all walks of life. On this perspective the
two value orientations might be argued to reflect different
attitudes towards the current and familiar state of affairs
and to the risks associated with change.
The societal protective outlook views the status
quo positively and as the right and proper state of
affairs. People are rightly rewarded for hard work;
they should be satisfied with their talents and abili-
ties, medicines are only for people who are ill and
people need to be protected from pressure to use
NE. In contrast, the proactionary sees change and
personal growth as a natural part of human motiva-
tion; human enhancement is a means to open up new
opportunities for individual and social development
and, if safe, enhancers should be consumer products.
These value orientations result in different evalua-
tions of the effects of NE on society. The
proactionary view accepts that NE will increase
competition between people and that it will be used
to cope with increasing demands in life; the protec-
tive outlook fears that enhancement will threaten
social cohesion.
The values of collectivism and individualism, once
taken to be mutually exclusive, are now recognised as
co-existing constructs both within cultures and individ-
uals [47]. For many of our respondents NE is viewed
through the two perspectives and simultaneously evokes
ideas of concern and promise. Parens makes a similar
point in a discussion of ethical frameworks that shape
people’s responses to issues like enhancement technol-
ogies. He identifies a gratitude framework (be thankful
for what we have) and a creativity framework (an obli-
gation to transform ourselves). But crucially, he argues
that Bnone of us who is thoughtful inhabits on only one
of these frameworks^ ([48]:38). This ambivalence sug-
gests that there is a need for broad societal engagement
with the questions raised by the prospect of enhance-
ment in various spheres of life.
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